Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0USILO
ADC Name
TAC-001
Synonyms
CD22 targeting TRAAC-Tallac Therapeutics; TAAC-001; TAC 001; TAC-001
   Click to Show/Hide
Organization
Tallac Therapeutics, Inc.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Mozistobart
  Antibody Info 
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Payload Name
Differentiated TLR-9 agonist (T-CpG)
  Payload Info 
Therapeutic Target
Toll-like receptor 9 (TLR9)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Undisclosed
Combination Type
zoratolimod
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05399654
Phase 1/2
A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05399654  Clinical Status Phase 1/2
Clinical Description A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.
References
Ref 1 A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors, NCT05399654